Tofacitinib: FDA panel recommends ulcerative colitis indication
March 14, 2018 | GI and Hepatology News
REPORTING FROM AN FDA ADVISORY COMMITTEE MEETING
“I think the safety concerns, though, they are dose dependent, the difference between the 5 [mg] and 10 [mg] were not large,” according to Dr. Pardi. “Several of these are mitigatable by dermatologic exam or, hopefully, a vaccine.”
Several of the advisory committee members submitted conflict of interest waivers. Chair Jean-Pierre Raufman, MD, and vice chair Darrell Pardi, MD, disclosed funding from competing pharmaceutical manufacturers.
Visit www.gastro.org/IBD for patient education guides that you can share with your ulcerative colitis patients.
